ExodusPoint Capital Management LP Buys New Position in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB)

ExodusPoint Capital Management LP bought a new stake in shares of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund bought 32,256 shares of the company’s stock, valued at approximately $253,000. ExodusPoint Capital Management LP owned about 0.07% of Y-mAbs Therapeutics at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also bought and sold shares of the stock. Principal Financial Group Inc. increased its position in shares of Y-mAbs Therapeutics by 9.4% during the 4th quarter. Principal Financial Group Inc. now owns 22,197 shares of the company’s stock valued at $174,000 after purchasing an additional 1,903 shares during the last quarter. JPMorgan Chase & Co. grew its position in Y-mAbs Therapeutics by 10.4% during the third quarter. JPMorgan Chase & Co. now owns 30,335 shares of the company’s stock valued at $399,000 after acquiring an additional 2,854 shares during the last quarter. SG Americas Securities LLC lifted its holdings in shares of Y-mAbs Therapeutics by 30.7% in the 4th quarter. SG Americas Securities LLC now owns 17,729 shares of the company’s stock worth $139,000 after acquiring an additional 4,163 shares during the last quarter. Charles Schwab Investment Management Inc. boosted its stake in shares of Y-mAbs Therapeutics by 1.8% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 284,540 shares of the company’s stock valued at $2,228,000 after purchasing an additional 4,963 shares in the last quarter. Finally, KLP Kapitalforvaltning AS bought a new position in shares of Y-mAbs Therapeutics during the 4th quarter valued at $46,000. Hedge funds and other institutional investors own 70.85% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms recently issued reports on YMAB. Morgan Stanley reduced their price target on Y-mAbs Therapeutics from $11.00 to $7.00 and set an “underweight” rating on the stock in a research report on Wednesday, March 5th. HC Wainwright decreased their target price on shares of Y-mAbs Therapeutics from $22.00 to $12.00 and set a “buy” rating on the stock in a research note on Friday, March 21st. Wedbush reissued an “outperform” rating and set a $23.00 price target on shares of Y-mAbs Therapeutics in a research report on Monday, March 3rd. Bank of America decreased their price objective on shares of Y-mAbs Therapeutics from $14.00 to $12.00 and set a “neutral” rating on the stock in a research report on Wednesday, March 5th. Finally, Truist Financial dropped their target price on shares of Y-mAbs Therapeutics from $21.00 to $18.00 and set a “buy” rating for the company in a report on Wednesday, March 5th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, seven have assigned a buy rating and two have assigned a strong buy rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $18.30.

Y-mAbs Therapeutics Stock Up 11.0 %

Shares of Y-mAbs Therapeutics stock opened at $4.83 on Monday. The firm has a market cap of $218.40 million, a price-to-earnings ratio of -8.94 and a beta of 0.71. Y-mAbs Therapeutics, Inc. has a twelve month low of $3.86 and a twelve month high of $17.78. The business has a 50-day moving average price of $5.18 and a 200-day moving average price of $8.75.

Y-mAbs Therapeutics (NASDAQ:YMAB) last released its quarterly earnings data on Tuesday, March 4th. The company reported ($0.15) EPS for the quarter, missing the consensus estimate of ($0.13) by ($0.02). Y-mAbs Therapeutics had a negative net margin of 28.22% and a negative return on equity of 24.61%. The business had revenue of $26.50 million for the quarter, compared to the consensus estimate of $26.70 million. During the same quarter last year, the business earned ($0.02) EPS. On average, equities analysts expect that Y-mAbs Therapeutics, Inc. will post -0.65 EPS for the current fiscal year.

Insider Activity

In related news, insider Thomas Gad sold 10,810 shares of Y-mAbs Therapeutics stock in a transaction that occurred on Friday, March 7th. The shares were sold at an average price of $5.23, for a total transaction of $56,536.30. Following the transaction, the insider now directly owns 202,721 shares of the company’s stock, valued at $1,060,230.83. This trade represents a 5.06 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Insiders own 22.50% of the company’s stock.

Y-mAbs Therapeutics Company Profile

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.